Bischloro<wbr/>anthrabenzo<wbr/>xocinone

Bischloroanthrabenzoxocinone

CAT N°: 19439
Price:

From 513.00 436.05

Bacterial type II fatty acid synthesis (FAS-II) is mediated by a series of enzymes, each of which may be targeted by potential antibiotics.{31077} Bischloroanthrabenzoxocinone (BABX) is an inhibitor of FAS-II, blocking fatty acid synthesis in S. aureus and E. coli with IC50 values of 11.4 and 35.3 µg/ml, respectively.{31076} It inhibits the growth of S. aureus and permeable E. coli strains with minimum inhibitory concentrations ranging from 0.2-0.4 µg/ml.{31076,31075} BABX also displays binding to liver X receptors (LXRs), inhibiting agonist binding in an LXR?-scintillation proximity assay (IC50 = 10 µM).{31075}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (6R,16R)-10,12-dichloro-6,7,9,16-tetrahydro-11,13,15-trihydroxy-3-methoxy-1,6,9,9-tetramethyl-6,16-epoxy-14H-anthra[2,3-d][1]benzoxocin-14-one
  • Correlated keywords
    • FAS-II staphylococcus FASII escherichia LXR-? LXRa LXR-a anti-biotic
  • Product Overview:
    Bacterial type II fatty acid synthesis (FAS-II) is mediated by a series of enzymes, each of which may be targeted by potential antibiotics.{31077} Bischloroanthrabenzoxocinone (BABX) is an inhibitor of FAS-II, blocking fatty acid synthesis in S. aureus and E. coli with IC50 values of 11.4 and 35.3 µg/ml, respectively.{31076} It inhibits the growth of S. aureus and permeable E. coli strains with minimum inhibitory concentrations ranging from 0.2-0.4 µg/ml.{31076,31075} BABX also displays binding to liver X receptors (LXRs), inhibiting agonist binding in an LXR?-scintillation proximity assay (IC50 = 10 µM).{31075}

We also advise you